{"id":"plain-aspirin","safety":{"commonSideEffects":[{"rate":"1-3","effect":"Gastrointestinal bleeding or ulceration"},{"rate":"5-10","effect":"Dyspepsia"},{"rate":"2-5","effect":"Nausea"},{"rate":"1-2","effect":"Hemorrhage (minor)"},{"rate":"0.5-1","effect":"Allergic reactions (in sensitive individuals)"},{"rate":"rare","effect":"Reye syndrome (in children with viral illness)"}]},"_chembl":{"chemblId":"CHEMBL25","moleculeType":"Small molecule","molecularWeight":"180.16"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Aspirin acetylates serine residues on COX-1 and COX-2 enzymes, permanently blocking their catalytic activity. This prevents the synthesis of prostaglandins (which mediate inflammation and pain) and thromboxane A2 (which promotes platelet aggregation). The antiplatelet effect is particularly important at low doses, where COX-1 inhibition in platelets predominates, making aspirin useful for cardiovascular protection.","oneSentence":"Aspirin irreversibly inhibits cyclooxygenase (COX) enzymes, reducing the production of prostaglandins and thromboxane to decrease inflammation, pain, and blood clotting.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:01:31.859Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myocardial infarction prevention and secondary prevention"},{"name":"Ischemic stroke prevention"},{"name":"Transient ischemic attack (TIA) prevention"},{"name":"Mild to moderate pain"},{"name":"Fever"},{"name":"Rheumatoid arthritis and other inflammatory conditions"}]},"trialDetails":[{"nctId":"NCT06541691","phase":"NA","title":"Coated or Chewable Aspirin and a Hybrid Strategy to Mitigate Adverse Effects of Air Pollution in Stable Atherosclerotic Disease","status":"RECRUITING","sponsor":"Rajaie Cardiovascular Medical and Research Center","startDate":"2024-03-06","conditions":"Atherosclerotic Cardiovascular Disease, Coronary Artery Disease, Ischemic Heart Disease","enrollment":3000},{"nctId":"NCT05343429","phase":"PHASE4","title":"Preoperative Aspirin and Benzydamine Hydrochloride Gargles on Severity and Duration of Post-Operative Sore Throat","status":"UNKNOWN","sponsor":"Rehman Medical Institute - RMI","startDate":"2022-04-01","conditions":"Sore Throat","enrollment":60},{"nctId":"NCT04744571","phase":"NA","title":"Safety and Efficacy of Drug-Coated Balloon Angioplasty for the Treatment of Chronic Total Occlusions","status":"UNKNOWN","sponsor":"Beijing Anzhen Hospital","startDate":"2021-02","conditions":"Coronary Artery Disease, Coronary Occlusion, Percutaneous Coronary Intervention","enrollment":200},{"nctId":"NCT04330872","phase":"PHASE4","title":"An Investigation Into The Impact Of Enteric Coated Of Aspirin In Patients With Newly Diagnosed Ischemic Stroke.","status":"COMPLETED","sponsor":"Hamad Medical Corporation","startDate":"2019-08-26","conditions":"Stroke, Ischemic","enrollment":42},{"nctId":"NCT01591486","phase":"","title":"Helicobacter Pylori and the Long-term Risk of Peptic Ulcer Bleeding","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"1995-01","conditions":"Bacterial Infection Due to Helicobacter Pylori (H. Pylori), Peptic Ulcer Bleeding","enrollment":904},{"nctId":"NCT01072604","phase":"PHASE1","title":"Pharmacokinetic Study Comparing Aspirin and Aspirin Granules","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-07","conditions":"Pharmacokinetics","enrollment":30},{"nctId":"NCT00531362","phase":"","title":"Enteric Coating as a Factor in Aspirin Resistance","status":"COMPLETED","sponsor":"Royal College of Surgeons, Ireland","startDate":"2007-09","conditions":"Cardiovascular Disease","enrollment":250}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":57,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Low dose of plain aspirin"],"phase":"marketed","status":"active","brandName":"Plain aspirin","genericName":"Plain aspirin","companyName":"Royal College of Surgeons, Ireland","companyId":"royal-college-of-surgeons-ireland","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aspirin irreversibly inhibits cyclooxygenase (COX) enzymes, reducing the production of prostaglandins and thromboxane to decrease inflammation, pain, and blood clotting. Used for Acute myocardial infarction prevention and secondary prevention, Ischemic stroke prevention, Transient ischemic attack (TIA) prevention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}